Skip to content
DeepViews

Repligen Corp (RGEN) — 分析摘要

Repligen Corp(RGEN)的市值为10.95十亿美元,最近一年的营收同比增长了+16.4%。净利润率为6.6%。当前市盈率为263.7倍。

核心要点

  • 营收同比变化+16.4%
  • 净利润率6.6%
  • 市盈率263.7倍

与BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)板块的其他公司相比,RGEN的营收增长为+16.4%,市盈率为263.7倍。

[XNAS]

Repligen Corp (RGEN)

$172.51

前收盘价 2026-10-12 · 市场数据 POLYGON · 财务数据 SEC EDGAR

市值
$10.95B
企业价值
$10.69B
市盈率
263.7
股息率
0.00%
EV/EBITDA
74.6
公司简介
关于
关于 Repligen Corp

Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, and other life science companies. It sells four main product categories: filtration and fluid management is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia-Pacific contribute about 44%, 37%, and 19% of revenue, respectively.

行业

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

员工人数

2,000

总部

WALTHAM, MA

Exchange

XNAS

官网
Source: Polygon.io
评分
竞争壁垒
竞争壁垒
40
窄护城河

基于 4 年财务数据的系统性竞争优势评估

此评估基于历史财务数据的量化分析,不构成投资建议。护城河评级可能随行业和竞争环境变化。

市场信号
估值
盈利
内部人交易
内部人备案活动

首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。

加载 SEC 内部人备案数据...
超级投资者
财务健康
财务健康

资本结构

总权益$2112.03M
总债务$551.05M
债务权益比0.26
现金及等价物$606.78M

现金流

经营现金流$134.86M
自由现金流$111.97M
自由现金流率14.26%
P/FCF 比率97.82
Source: Polygon.io · SEC EDGAR
股息
最新资讯
Recent News

免责声明:本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。